Tokyo (SCCIJ)—The Swiss company CeQur has concluded a venture capital funding round of 120 million US dollars, the largest equity financing for a smaller company incorporated in Switzerland in 2025. The company has developed a patch that administers insulin without injection for four days.
Growing adoption
The medical device company from Horw in the canton of Lucerne, with US operational headquarters in Greenville, South Carolina, is dedicated to simplifying insulin delivery for diabetes patients who need multiple daily injections. CeQur has seen growing adoption of its Simplicity patch, a discreet, easy-to-use bolus insulin delivery solution, with over 6,000 patients currently using it.
The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams, and allow outreach initiatives to bring Simplicity to more healthcare providers and patients managing diabetes. CeQur’s 3,700-square-meter automated cleanroom facility completed all qualifications by the end of 2024 and will start manufacturing commercial products this year.
Reaching more patients
Also, CeQur will continue to grow its sales force and expand its clinical team. “This financing will enable us to reach more patients, expand our commercial footprint, and continue innovating solutions that simplify mealtime insulin management,” said Mike Rubino, CeQur’s Chief Financial Officer.
Additionally, CeQur is increasing and improving pharmacy access. Besides having more than two-thirds of commercially insured patients on formulary, CeQur has reached agreements with numerous Medicare Part-D and State Medicaid programs in the United States. More than 80 percent of all claims are covered as a pharmacy benefit. The average co-pay is less than 45 dollars per month.
Support of diabetes patients
One Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, twelve daily mealtime injections over four days. Clinical research has shown that nearly 90 percent of patients using Simplicity reported following their insulin regimen better than multiple daily injections. The Patch is clinically proven to improve glycemic control.
CeQur did not disclose the investors in this most recent funding. In April 2021, the company received 115 million US dollars in a series C5 financing round, the largest fundraising for a privately held medtech company in Europe until that date. The round was led by Credit Suisse Entrepreneur Capital (Zurich) and Endeavour Vision (Geneva, Minneapolis), alongside existing investors Schroder & Co. Bank (Zurich) and VI Partners (Altendorf in the canton of Schwyz).
There was also “significant participation from new investors.”. These included Tandem Diabetes Care (San Diego, USA), Ypsomed Group (Burgdorf in the canton of Bern), Federated Hermes Kaufmann Funds (USA), Kingdon Capital (USA), and GMS Capital (Washington D.C., USA).
Text: CeQuur (Editing by SCCIJ)
